Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.58 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762926 | 0.85 | KAT8 (0.56) | ADORA2AADORA1ADORA3ADORA2BKAT8 | |
| SCHEMBL930507 | 0.82 | ADORA2A (0.62) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL2764032 | 0.80 | ADORA2A (0.58) | ADORA2AADORA1ADORA3ADORA2BKAT8 | |
| SCHEMBL2762872 | 0.80 | ADORA2A (0.59) | ADORA2AADORA1ADORA3ADORA2BKAT8 | |
| SCHEMBL2783816 | 0.80 | ADORA2A (0.58) | ADORA2AADORA1ADORA3ADORA2BKAT8 | |
| SCHEMBL928179 | 0.79 | ADORA2A (0.74) | ADORA2AADORA1ADORA3ADORA2B | |
| Lithium SCHEMBL930354 | 0.79 | ADORA2A (0.57) | ADORA2AADORA1ADORA3ADORA2BKAT8 | |
| SCHEMBL930353 | 0.79 | ADORA2A (0.57) | ADORA2AADORA1ADORA3ADORA2BKAT8 | |
| SCHEMBL928950 | 0.79 | ADORA2A (0.67) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL929521 | 0.78 | ADORA2A (0.58) | ADORA2AADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1720553-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R&D) LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005079801-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R & D) LTD (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.